Arianna Rubin-Means, MPH, PhD

Assistant Professor, Global Health

Dr. Arianna Rubin-Means, MPH, PhD focuses on generating operational evidence needed to improve the delivery of routine primary healthcare programs in low and middle-income countries, both within health facilities and in communities. She is currently the implementation science lead for the DeWorm3 Project, a series of large hybrid cluster randomized trials in Benin, India, and Malawi. She designs and manages the DeWorm3 Project’s qualitative research studies, organizational readiness research, operational research process mapping studies, and economic evaluations. She also leads implementation science activities for a multi-country network of facility-based child mortality studies, which aim to improve care for acutely ill children living in countries with limited resources and prevent both in-hospital and post-discharge mortality. Dr. Means teaches the online Fundamentals of Implementation Science course, providing training to over 200 implementation scientists around the world, as well as the annual CFAR implementation science mini-course.

A trained epidemiologist and implementation scientist, Dr. Means’ area of expertise is integrating evaluation of implementation outcomes into clinically oriented research to ensure that findings translate into the evidence needed to inform policy and guidelines. Dr. Means is a Scientific Associate at the Natural History Museum in London and an Associate Editor for PLOS Neglected Tropical Diseases.

Publications

  1. Aruldas, K, Ramesh, RM, Prasad, S, Israel, GJ, Legge, H, Walson, JL et al.. School-based deworming programmes: Knowledge and perceptions regarding soil-transmitted helminth infections among schoolteachers in Tamil Nadu, India. PLOS Glob Public Health. 2025;5 (3):e0004319. doi: 10.1371/journal.pgph.0004319. PubMed PMID:40163421 PubMed Central PMC11957371.
  2. Khosropour, CM, Means, AR, Kerani, RP, Murphy, EM, Mehta, K, Santana, K et al.. Developing Implementation Science Capacity Within Health Departments Located in Ending the HIV Epidemic Priority Areas. J Acquir Immune Defic Syndr. 2025;98 (5S):e216-e221. doi: 10.1097/QAI.0000000000003617. PubMed PMID:40163073 .
  3. Coe, MM, Yoshioka, E, Odhiambo, D, Masheti, M, Amam, P, Nyaoke, J et al.. Factors influencing provider deviation from national HIV and nutritional guidelines for HIV-exposed children in western Kenya: a qualitative study. BMC Health Serv Res. 2024;24 (1):1473. doi: 10.1186/s12913-024-11942-9. PubMed PMID:39593037 PubMed Central PMC11600710.
  4. Emerson, PM, Evans, D, Freeman, MC, Hanson, C, Kalua, K, Keiser, J et al.. Need for a paradigm shift in soil-transmitted helminthiasis control: Targeting the right people, in the right place, and with the right drug(s). PLoS Negl Trop Dis. 2024;18 (10):e0012521. doi: 10.1371/journal.pntd.0012521. PubMed PMID:39432840 PubMed Central PMC11493411.
  5. Means, AR, Ásbjörnsdóttir, KH, Sharrock, KC, Galagan, SR, Aruldas, K, Avokpaho, E et al.. Coverage of community-wide mass drug administration platforms for soil-transmitted helminths in Benin, India, and Malawi: findings from the DeWorm3 project. Infect Dis Poverty. 2024;13 (1):72. doi: 10.1186/s40249-024-01241-0. PubMed PMID:39380086 PubMed Central PMC11460046.
Search PubMed

Comments are closed.